<DOC>
	<DOCNO>NCT00005104</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether reduction serum insulin level metformin increase ovulatory response clomiphene citrate woman polycystic ovary syndrome .</brief_summary>
	<brief_title>Randomized Study Decreased Hyperinsulinemia Ovulatory Response Clomiphene Citrate Women With Polycystic Ovary Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients randomize one two treatment arm . Patients receive oral metformin oral placebo three time daily 7 week . Patients remain anovulatory day 49 receive metformin placebo plus escalating dos oral clomiphene citrate daily 5 consecutive day , begin day 50 , 80 , 110 . Following ovulation , treatment clomiphene citrate metformin placebo continue 6 ovulatory cycle occur , pregnancy occurs , anovulation persists . Patients receive placebo arm ovulate high dose clomiphene citrate may cross receive metformin 6 week washout .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Patients chronic anovulation due polycystic ovary syndrome ( PCOS ) fail clomiphene citrate Must oligoovulation hyperandrogenemia Prior/Concurrent Therapy Endocrine therapy : At least 2 month since prior clomiphene citrate Other : At least 2 month since prior standard therapy ( include counter drug ) At least 2 month since prior investigational drug Prior multi/prenatal vitamin allow Patient Characteristics Hematopoietic : Hematocrit great 38 % Hepatic : Liver function normal No clinically significant hepatic disease Renal : No clinically significant renal disease Creatinine le 1.4 mg/dL No proteinuria Cardiovascular : No clinically significant cardiac disease Pulmonary : No clinically significant pulmonary disease Hormonal : Thyroid function normal Prolactin normal Estradiol normal Fasting 17 alphahydroxy progesterone le 200 ng/dL OR No late onset adrenal hyperplasia 21 alphahydroxylase deficiency Other : Not pregnant Negative pregnancy test Male partner must normal semen analysis WHO criteria Must acceptable health interview , medical history , physical exam , laboratory test No diabetes mellitus No clinically significant neurologic , psychiatric , infectious , neoplastic , metabolic disease No clinically significant malignant disease except nonmelanomatous skin cancer At least 1 year since prior drug abuse alcoholism</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>endocrine disorder</keyword>
	<keyword>hyperinsulinism</keyword>
	<keyword>polycystic ovarian syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>